A Study To Assess The Safety And Effectiveness Of Prevenar In Chinese Children Who Have Not Previously Received A Vaccine Against Pneumococcal Bacteria

A Phase 4, Open-label Trial to Assess the Safety, Tolerability and Immunogenicity of Prevenar in Older Infants and Young Children in China Who Are Naive to Previous Pneumococcal Vaccination.

A vaccine called Prevenar is already approved for use in China for vaccination of children younger than 6 years old against infections caused by Streptococcus pneumoniae.

This study is to measure the amount of antibodies (antibodies help people fight off diseases) Chinese children aged between 121 days and 6 years (72 months) produce when given Prevenar. The study will also provide more data on how safe and well tolerated Prevenar is in Chinese children.

Inclusion Criteria:

• Healthy Chinese male or female subjects.
• Between 121 days to less than 72 months of age at the time of entry into the study.

Exclusion Criteria:

• Receipt of previous vaccine against Pneumo
• Previous anaphylactic reaction to any vaccine or part of a vaccine
• Previous proven invasive Pneumo infection
• Receipt of investigational drug or device within the proceeding 28 days